桥接治疗强度与多发性骨髓瘤BCMA CAR-T治疗后造血恢复受损相关
这项多中心国际观察性研究纳入158例接受BCMA CAR-T治疗的复发/难治多发性骨髓瘤患者,按桥接方案中细胞毒性化疗药物数量分为非CTX、中等CTX(1-2种)和强化CTX(≥3种或高剂量化疗联合干细胞移植),发现CTX药物数量与CAR-T后造血恢复受损相关,强化CTX桥接与中性粒细胞和血小板恢复时间延长、严重感染易感性增加及严重晚期血细胞减少风险显著增加相关。
要点
- 桥接方案中细胞毒性化疗药物数量越多,CAR-T后造血恢复受损越明显,尤其体现在晚期。
- 强化CTX桥接与中性粒细胞和血小板恢复时间延长及独特恢复模式(如二次下降的间歇表型)相关。
- 强化CTX桥接与严重感染易感性增加及严重晚期血细胞减少风险显著增加相关。
核心结论
- 桥接治疗强度明显影响BCMA CAR-T治疗后造血恢复轨迹。
- 靶向和新型免疫治疗或可作为桥接替代方案,高危患者可能尤其受益于加强监测、预防和支持治疗。
研究设计与样本
- 多中心国际观察性研究,纳入158例接受BCMA导向CAR-T治疗的复发/难治多发性骨髓瘤患者。
- 根据桥接方案是否暴露于经典细胞毒性化疗(CTX)及CTX药物数量,分为非CTX、中等CTX(1-2种CTX药物)和强化CTX(≥3种CTX药物或高剂量治疗联合干细胞移植)。
主要发现
- CTX药物数量与CAR-T后造血恢复受损相关,累及多个造血细胞谱系,尤其在CAR-T后晚期明显。
- 强化CTX桥接与中性粒细胞和血小板恢复时间延长相关。
- 强化CTX桥接与独特造血恢复模式相关,例如以二次下降为特征的间歇表型。
- 强化CTX桥接与严重感染易感性增加相关。
- 在单因素和多因素模型中,强化CTX桥接与严重晚期血细胞减少风险显著增加相关。
临床怎么用
- 靶向和新型免疫治疗或可作为桥接替代方案。
- 高危患者可能尤其受益于加强监测、预防和支持治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR-T infusion often necessitates bridging therapies. Because of limited knowledge about the effects of bridging on post-CAR-T clinical course and outcomes, the selection of treatment options is challenging. In this multicenter international observational study, we explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with RRMM treated with B-cell maturation antigen (BCMA)-directed CAR-T therapy. Based on exposure to classical cytotoxic (CTX) chemotherapy, we classified bridging regimens as non-CTX, intermediate CTX (1-2 CTX agents), or intensive CTX (≥3 CTX agents or high-dose therapy with stem cell transplantation). We found associations between the number of CTX agents used and impaired post-CAR-T hematopoietic reconstitution, evident across hematopoietic cell lineages and particularly manifesting during the late post-CAR-T period. Intensive CTX bridging was associated with a prolonged time to neutrophil and platelet recovery, distinct patterns of hematopoietic recovery (eg, an intermittent phenotype characterized by a second drop), an increased susceptibility to severe infections and a significantly increased risk for severe late cytopenias in univariate and multivariate models. Taken together, these results highlight that bridging intensity distinctly shapes the trajectory of hematopoietic recovery after BCMA CAR-T therapy. Targeted and novel immunotherapies could provide alternatives for bridging, and high-risk patients may particularly benefit from enhanced monitoring, prophylaxis, and supportive care.
引用
- Frenking JH, Zhou X, Rejeski K, et al. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025. PMID: 40267180. doi:10.1182/bloodadvances.2024015732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。